Utility of baseline 18FDG-PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphomaLuca Ceriani, Emanuele Zucca, Maurizio Martelli et al.|Blood|2015Cited by 177
Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana LinfomiCarlo Visco, Umberto Vitolo, Annalisa Chiappella et al.|The Lancet Haematology|2016Cited by 139
Direct-Acting Antivirals in Hepatitis C Virus-Associated Diffuse Large B-cell LymphomasMichele Merli, Luca Arcaini, Annalisa Arcari et al.|The Oncologist|2018Cited by 69
Rituximab Dose-Dense Chemotherapy Followed by Intensified High-Dose Chemotherapy and Autologous Stem Cell Transplantation (HDC+ASCT) Significantly Reduces the Risk of Progression Compared to Standard Rituximab Dose-Dense Chemotherapy As First Line Treatment in Young Patients with High-Risk (aa-IPI 2–3) Diffuse Large B-Cell Lymphoma (DLBCL): Final Results of Phase III Randomized Trial DLCL04 of the Fondazione Italiana Linfomi (FIL)Umberto Vitolo, Maurizio Martelli, Annalisa Chiappella et al.|Blood|2012Cited by 30
Rituximab, Bendamustine and Cytarabine (RBAC500) As Induction Therapy in Elderly Patients with Mantle Cell Lymphoma: Final Results of a Phase 2 Study from the Fondazione Italiana LinfomiCarlo Visco, Umberto Vitolo, Annalisa Chiappella et al.|Blood|2016Cited by 3